Ares_M
No personal profile
19Follow
4Followers
0Topic
0Badge
I don´t see Meta going anywhere, if the metaverse evolves to something similar as seen in Ready Player Number One it will be through Google, Microsoft or Sony. On the other hand Snap approach as a VR makes much more sense but still I wouldn´t bet on them to be the most profitable for extensive VR applications/impementations
Sorry, the original content has been removed
$Etsy(ETSY)$ taking advantage of the post-earnings debacle bounce
Well perhaps if they hadn´t pushed expats out and increased stamp duties to 60% among other things, Singapore would remain attractive as a place to place your money.
Singapore Says Foreign Residents’ Deposits Fell by S$22 Billion
$NIO Inc.(NIO)$ neat 30% up
$Aethlon Medical(AEMD)$amazing pre-market trading session but the results of the clinical test sparking this boost makes AEMD like a solid company to invest on the long run
$Invitae(NVTA)$¿End of Invitae's uptrend for now?
$Sphere 3D(ANY)$playing safe
Tesla isn't a hot stock for now and the short term, things look bad for them in China with government pushing an anti-Tesla campaign and setting standards to favor local EV brands, tariff war is back while Chinese brands are already landing in Europe, now Norway fines TSLA...
Tesla shares rose nearly 1%,after setting up China site to store data locally
Time to buy some more at a very attractive price per share
Palantir stock pulls back despite Q1 revenue beat, upside sales guidance
$Eledon Pharmaceuticals, Inc.(ELDN)$ 50% gain
$Digital Brands Group, Inc.(DBGI)$diamond hands here, this company is gonna keep growing through Amazon. Holding it till 2022 and maybe beyond!
Great frist results from $CRISPR Therapeutics AG(CRSP)$& $Vertex(VTNR)$study on gen editing therapy to cure Thalssemia.CRSP is a clear win for 5y+ investors and has a massive growth ahead for the next 10 years, as a Biologist I can't but agree on the 9X figures.“This approach uses CRISPR/Cas9 gene editing to enable the patient’s own cells to produce fetal hemoglobin, and to see results that demonstrate the potential for a treatment that may transform the lives of many patients is an exciting time for me and the team.”https://www.businesswire.com/news/home/20210611005069/en/Vertex-and-CRISPR-Therapeutics-Present-New-Data-in-22-Patients-With-Greater-Than-3-Months-Follow-Up-Post-Treatment-With-Invest
Go to Tiger App to see more news